Anvive develops effective vaccine against Valley Fever in dogs
by Katie Pfaff
Pet health technology company, Anivive Lifesciences Inc., reports 100% protection based on results from its antifungal vaccine for canine Valley Fever. The study met its primary endpoint and found that the vaccine prevented clinical disease in dogs vaccinated.
"This study provides important data that validates our model and demonstrates the ability of the vaccine to afford protection against exposure to an extremely virulent fungal pathogen," said Anivive Chief Medical Officer David Bruyette, DVM, DACVIM. "To date, no vaccine exists to protect against systemic fungal disease, so this is an important step forward in our progress to develop a vaccine for Valley Fever and other fungal diseases in animals and humans."
The blinded, randomized, and placebo-controlled study included dogs given the study vaccine and tested with a fungus that causes a systemic disease called Valley Fever. The strain, Coccidioides, used in the study can cause the disease. Study canines were given a booster injection one month later.
Dogs were tested for fungal burden, radiographic changes, gross and histopathological lung lesions. Among the vaccinated groups, all measures were reduced, and dogs did not develop clinical disease. Some 30 million dogs are thought to be at risk for the disease based on the geographic location of fungal spores.
Comments
Related Articles
Copyright © 2026 - All Rights Reserved
ISSN 2768-198X
List
Add
Please enter a comment